Smith & Nephew SNATS, Inc. (NYSE:SNN – Get Free Report) declared a dividend on Thursday, March 5th. Shareholders of record on Friday, March 27th will be paid a dividend of 0.482 per share by the medical equipment provider on Wednesday, May 27th. This represents a dividend yield of 281.0%. The ex-dividend date is Friday, March 27th.
Smith & Nephew SNATS has raised its dividend payment by an average of 0.0%annually over the last three years. Smith & Nephew SNATS has a payout ratio of 26.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Smith & Nephew SNATS to earn $2.00 per share next year, which means the company should continue to be able to cover its $0.57 annual dividend with an expected future payout ratio of 28.5%.
Smith & Nephew SNATS Price Performance
NYSE SNN traded down $0.60 during mid-day trading on Friday, hitting $34.25. The company’s stock had a trading volume of 414,074 shares, compared to its average volume of 955,770. The company has a current ratio of 2.57, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 52-week low of $23.91 and a 52-week high of $38.79. The stock’s fifty day simple moving average is $34.40 and its two-hundred day simple moving average is $34.95.
Institutional Trading of Smith & Nephew SNATS
About Smith & Nephew SNATS
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
Further Reading
- Five stocks we like better than Smith & Nephew SNATS
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- Your name isn’t on our protected list yet
- What Expenses Can Be Deducted From Capital Gains Tax This Year?
Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.
